Invention Grant
US08012730B1 Specific lysis of staphylococcal pathogens by bacteriophage phi11 endolysin
失效
通过噬菌体phi11细胞内溶素特异性溶解葡萄球菌病原体
- Patent Title: Specific lysis of staphylococcal pathogens by bacteriophage phi11 endolysin
- Patent Title (中): 通过噬菌体phi11细胞内溶素特异性溶解葡萄球菌病原体
-
Application No.: US11511848Application Date: 2006-08-29
-
Publication No.: US08012730B1Publication Date: 2011-09-06
- Inventor: David M. Donovan
- Applicant: David M. Donovan
- Applicant Address: US DC Washington
- Assignee: The United States of America as represented by the Secretary of Agriculture
- Current Assignee: The United States of America as represented by the Secretary of Agriculture
- Current Assignee Address: US DC Washington
- Agent John D. Fado; Evelyn M. Rabin
- Main IPC: C12N9/14
- IPC: C12N9/14 ; C07H21/04

Abstract:
The Staphylococcus aureus bacteriophage phi11 endolysin has two peptidoglycan hydrolase domains (endopeptidase and amidase) and a SH3b cell wall-binding domain. In turbidity reduction assays, the purified protein can lyse untreated staphylococcal mastitis-causing pathogens, S. aureus and coagulase negative staphylococci (S. chronogenes, S. epidermis, S. hyicus, S. simulans, S. warneri, and S. xylocus), making it a strong antimicrobial protein and an effective candidate for treating multidrug-resistant staphylococci. Lytic activity is maintained at the pH (6.7) and the ‘free’ calcium concentration (3 mM) of milk. Truncated endolysin-derived proteins, containing just the endopeptidase domain, also lyse staphylococci, in the absence of the SH3b-binding domain.
Information query